Q: Should N-acetylcysteine be used routinely to prevent contrast-induced acute kidney injury?

Cleveland Clinic Journal of Medicine

Volumn 79, Issue 11, 2012, Pages 746-749

  Sivalingam, Senthil K ^a   Hariharan, Mini V ^b   Braden, Gregory L ^a   Freda, Benjamin J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PONDICHERRY INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; CHEMICALLY INDUCED DISORDER; HUMAN; INTRAVENOUS ADMINISTRATION; NOTE; PRACTICE GUIDELINE; RISK ASSESSMENT;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ADMINISTRATION, INTRAVENOUS; ANAPHYLAXIS; CONTRAST MEDIA; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84872255177     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79a.12088     Document Type: Note

References (13)

1. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 2011;124:1250-1259.
2. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004;148:422-429.
3. Tepel M, Van Der Giet M, Schwarzfeld C, Laufer U, Hermann D, Zidek W. Prevention of radiographic-contrastagent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
4. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-1388.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2012;2(suppl 1):1-138.
6. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
7. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight A. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-2118.
8. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782.
9. Gurm HS, Smith DE, Berwanger O, et al; BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2012;5:98-104.
10. Duong MH, MacKenzie TA, Malenka DJ. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrastinduced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 2005;54:471-479.
11. Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007;5:32.
12. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574-e651.
13. Kanter MZ. Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am J Health Syst Pharm 2006;63:1821-1827.